FDA: Page 31
-
In rare move, Gilead gives up 'orphan' status for experimental coronavirus drug
After sparking controversy, the biotech asked the FDA to rescind a designation designed to encourage research into therapies for rare diseases.
By Jonathan Gardner • March 25, 2020 -
Leukemia drug from Roche, AbbVie extends survival, study finds
Paired with chemotherapy, Venclexta succeeded in a Phase 3 acute myeloid leukemia trial just weeks after falling short in another combination study.
By Jonathan Gardner • March 23, 2020 -
Remdesivir, chloroquine move to forefront as White House tries to speed coronavirus response
Neither drug is approved for COVID-19, but officials seek to quickly study both in hopes of finding an answer for U.S. coronavirus patients.
By Jonathan Gardner • March 19, 2020 -
FDA scales back domestic inspections amid coronavirus outbreak
The agency's announcement comes a little over a week after it postponed nearly all overseas inspections, which are a critical oversight tool.
By Kristin Jensen • March 19, 2020 -
Jacob Bell/BioPharma Dive
FDA maps out plan for trials as coronavirus starts to threaten drug research
The agency is trying to get ahead of what could be widespread protocol changes to ongoing clinical trials.
By Ben Fidler • March 18, 2020 -
Courtesy of Regeneron Pharmaceuticals
Regeneron and Sanofi speed Kevzara into coronavirus trials
Positive signs from a Chinese test of Roche's Actemra support the companies' decision to start studying their anti-inflammatory drug against COVID-19.
By Jonathan Gardner • March 16, 2020 -
Yujin Kim / MedTech Dive, original photo courtesy of U.S. Food and Drug Administration
Coronavirus spread prompts FDA to postpone nearly all overseas inspections
The agency's decision was based on U.S. government travel restrictions, but it said "alternative tools and methods" will help it maintain oversight.
By Jonathan Gardner • March 10, 2020 -
Brian Tucker/BioPharma Dive
FDA, FTC put drugmakers on notice about tactics to block biosimilars
A joint agency meeting called out deceptive advertising and anti-competitive practices that may have kept the U.S. from catching up to Europe in establishing a market for lower-priced biologics.
By Jonathan Gardner • March 9, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from https://www.flickr.com/photos/nihgov/49565662436/in/album-72157713108522106/.
Tracking biopharma's response to the new coronavirus
The ongoing outbreak is a huge test for the biopharmaceutical industry and its ability to supply, develop, and test new drugs without disruption. Keep up with all of BioPharma Dive's coverage here.
By Jacob Bell • Updated July 7, 2020 -
Courtesy of Centers for Disease Control and Prevention
$8.3B in coronavirus funding set in motion as federal agencies ramp up response
The bill approved by both houses of Congress provides more than $2 billion to BARDA, and requires treatments developed using taxpayer money be available to the U.S. government at a "fair and reasonable price."
By Shannon Muchmore • Updated March 5, 2020 -
Courtesy of Sanofi
Sanofi wins US approval for myeloma drug key to its cancer ambitions
Sarclisa is the first cancer drug wholly owned by Sanofi to win an FDA OK in a decade — a milestone in the pharma's bid to play a larger role in oncology.
By Ned Pagliarulo • March 2, 2020 -
FDA seeks 'right balance' as it allows immediate use of coronavirus tests
"We are not changing our standards for issuing emergency use authorizations," said agency chief Stephen Hahn as the FDA works to expand U.S. testing.
By Susan Kelly • March 2, 2020 -
FDA reports first drug shortage due to coronavirus impact
Supplies of the drug, which the FDA did not identify, ran short as a result of issues at a site that produces the active ingredient. Other options are available, the agency said.
By Ned Pagliarulo • Updated March 2, 2020 -
Yujin Kim / MedTech Dive, original photo courtesy of U.S. Food and Drug Administration
FDA pushes back decision on Zogenix epilepsy drug
Shares sank on concerns about the future of the drug designed to treat Dravet syndrome, a rare form of epilepsy.
By Kristin Jensen • Feb. 27, 2020 -
Jacob Bell/BioPharma Dive
FDA monitoring impact of coronavirus outbreak on medical product supply
The agency postponed drug and device inspections in China that were scheduled for February, limiting its oversight of a key country in the medical supply chain.
By Nick Paul Taylor • Feb. 18, 2020 -
Jacob Bell/BioPharma Dive
Cancer concerns knock Eisai's weight loss drug from market
Eisai has agreed to remove Belviq after the FDA said a post-marketing study found a "range of cancer types" appeared to develop more frequently in patients taking the drug.
By Jacob Bell • Feb. 14, 2020 -
Biogen dips as Alzheimer's drugs from Lilly, Roche fail again
Analysts have said that, should the DIAN-TU study miss, it may further paint Biogen's aducanumab and the positive Phase 3 data it generated as an "artifact of luck" within a series of failed amyloid-targeting drugs.
By Jacob Bell • Feb. 10, 2020 -
FDA approves Aimmune drug as first treatment for peanut allergy
Aimmune's next challenge will be securing insurance coverage as people allergic to peanuts still have to avoid exposure to the food.
By Jonathan Gardner • Jan. 31, 2020 -
FDA, expecting a gene therapy boom, firms up policies
In seven guidance documents, the agency gave drugmakers guidelines on manufacturing, testing and long-term follow-up for the one-time treatments.
By Ned Pagliarulo • Jan. 28, 2020 -
FDA decision nears on Aimmune's contested peanut allergy drug
Palforzia is one of two products under review by the FDA that are aimed at desensitizing people highly allergic to peanuts.
By Jonathan Gardner • Jan. 24, 2020 -
Epizyme drug granted approval by FDA for rare cancer
Five years after buying back rights from Eisai, Epizyme won approval for its first-ever drug.
By Ned Pagliarulo • Updated Jan. 24, 2020 -
Kendall Davis/BioPharma Dive
While expected, Intercept's approval delay adds to NASH uncertainty
An upcoming FDA advisory meeting will be a key test for Intercept's ambitions to become the first drugmaker with an approved therapy for the liver disease.
By Jacob Bell • Jan. 17, 2020 -
Nektar quickly drops opioid drug after FDA panel rejection
After a decade of research, the biotech said it will withdraw its application for oxycodegol and make no further investment in the drug.
By Kristin Jensen • Jan. 15, 2020 -
Ultragenyx boosted by trial data for 2nd gene therapy
One analyst called the results, which sparked a 30% jump in Ultragenyx's stock price, better than expected. The biotech is now preparing a Phase 3 trial.
By Jonathan Gardner • Jan. 10, 2020 -
Yujin Kim / MedTech Dive, original photo courtesy of U.S. Food and Drug Administration
5 trends to watch at the FDA in 2020
With Stephen Hahn confirmed as commissioner, the regulator is better positioned to more firmly address political pressures and a rising tide of complex medicines.
By Jonathan Gardner • Jan. 9, 2020
Previous
